TY - JOUR
T1 - Early nasal microbiota and subsequent respiratory tract infections in infants with cystic fibrosis
AU - SCILD Study Group
AU - BILD study group
AU - Steinberg, Ruth
AU - Mostacci, Nadja
AU - Kieninger, Elisabeth
AU - Frauchiger, Bettina
AU - Casaulta, Carmen
AU - Usemann, Jakob
AU - Moeller, Alexander
AU - Trachsel, Daniel
AU - Rochat, Isabelle
AU - Blanchon, Sylvain
AU - Mueller-Suter, Dominik
AU - Kern, Barbara
AU - Zanolari, Maura
AU - Frey, Urs
AU - Ramsey, Kathryn A.
AU - Hilty, Markus
AU - Latzin, Philipp
AU - Korten, Insa
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/11/23
Y1 - 2024/11/23
N2 - Background: Respiratory tract infections (RTIs) drive lung function decline in children with cystic fibrosis (CF). While the respiratory microbiota is clearly associated with RTI pathogenesis in infants without CF, data on infants with CF is scarce. We compared nasal microbiota development between infants with CF and controls and assessed associations between early-life nasal microbiota, RTIs, and antibiotic treatment in infants with CF. Methods: We included 50 infants with CF and 30 controls from two prospective birth cohorts followed throughout the first year of life. We collected 1511 biweekly nasal swabs and analyzed the microbiota after amplifying the V3–V4 region of the 16S rRNA gene. We conducted structured weekly interviews to assess respiratory symptoms and antibiotic treatment. We calculated generalized additive mixed models and permutational analysis of variance. Results: Here, we show that the nasal microbiota is already altered before the first RTI or antibiotic treatment in infants with CF. Microbiota diversity differs between infants with CF and controls following RTIs and/or antibiotic treatment. CF infants with lower α-diversity have a higher number of subsequent RTIs. Conclusions: Early nasal microbiota alterations may reflect predisposition or predispose to RTIs in infants with CF, and further change after RTIs and antibiotic treatment. This highlights the potential of targeting the nasal microbiota in CF-related RTI management, while also questioning current practices in the era of novel modulator therapies.
AB - Background: Respiratory tract infections (RTIs) drive lung function decline in children with cystic fibrosis (CF). While the respiratory microbiota is clearly associated with RTI pathogenesis in infants without CF, data on infants with CF is scarce. We compared nasal microbiota development between infants with CF and controls and assessed associations between early-life nasal microbiota, RTIs, and antibiotic treatment in infants with CF. Methods: We included 50 infants with CF and 30 controls from two prospective birth cohorts followed throughout the first year of life. We collected 1511 biweekly nasal swabs and analyzed the microbiota after amplifying the V3–V4 region of the 16S rRNA gene. We conducted structured weekly interviews to assess respiratory symptoms and antibiotic treatment. We calculated generalized additive mixed models and permutational analysis of variance. Results: Here, we show that the nasal microbiota is already altered before the first RTI or antibiotic treatment in infants with CF. Microbiota diversity differs between infants with CF and controls following RTIs and/or antibiotic treatment. CF infants with lower α-diversity have a higher number of subsequent RTIs. Conclusions: Early nasal microbiota alterations may reflect predisposition or predispose to RTIs in infants with CF, and further change after RTIs and antibiotic treatment. This highlights the potential of targeting the nasal microbiota in CF-related RTI management, while also questioning current practices in the era of novel modulator therapies.
UR - http://www.scopus.com/inward/record.url?scp=85210099051&partnerID=8YFLogxK
U2 - 10.1038/s43856-024-00616-6
DO - 10.1038/s43856-024-00616-6
M3 - Article
C2 - 39580540
AN - SCOPUS:85210099051
SN - 2730-664X
VL - 4
JO - Communications Medicine
JF - Communications Medicine
M1 - 246
ER -